English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/109990
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorKosaka, Priscila M.-
dc.contributor.authorPini, Valerio-
dc.contributor.authorRuz Martínez, José Jaime-
dc.contributor.authorSilva, Rubens A. da-
dc.contributor.authorGonzález Sagardoy, María Ujué-
dc.contributor.authorRamos Vega, Daniel-
dc.contributor.authorCalleja, Montserrat-
dc.contributor.authorTamayo de Miguel, Francisco Javier-
dc.identifier.citationNature Nanotechnology 9: 1047–1053 (2014)es_ES
dc.description.abstractBlood contains a range of protein biomarkers that could be used in the early detection of disease. To achieve this, however, requires sensors capable of detecting (with high reproducibility) biomarkers at concentrations one million times lower than the concentration of the other blood proteins. Here, we show that a sandwich assay that combines mechanical and optoplasmonic transduction can detect cancer biomarkers in serum at ultralow concentrations. A biomarker is first recognized by a surface-anchored antibody and then by an antibody in solution that identifies a free region of the captured biomarker. This second antibody is tethered to a gold nanoparticle that acts as a mass and plasmonic label; the two signatures are detected by means of a silicon cantilever that serves as a mechanical resonator for ‘weighing’ the mass of the captured nanoparticles and as an optical cavity that boosts the plasmonic signal from the nanoparticles. The capabilities of the approach are illustrated with two cancer biomarkers: the carcinoembryonic antigen and the prostate specific antigen, which are currently in clinical use for the diagnosis, monitoring and prognosis of colon and prostate cancer, respectively. A detection limit of 1 × 10−16 g ml−1 in serum is achieved with both biomarkers, which is at least seven orders of magnitude lower than that achieved in routine clinical practice. Moreover, the rate of false positives and false negatives at this concentration is extremely low, ∼10−4.es_ES
dc.description.sponsorshipWe acknowledge financial support from the Spanish Science Ministry (MINECO) through projects MAT2012-36197 and INMUNO-SWING ITP-2011-0821-010000; and from European Research Council through Starting Grant NANOFORCELLS (ERC-StG-2011-278860).es_ES
dc.publisherNature Publishing Groupes_ES
dc.titleDetection of cancer biomarkers in serum using a hybrid mechanical and optoplasmonic nanosensores_ES
dc.description.peerreviewedPeer reviewedes_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderEuropean Commission-
Appears in Collections:(IMN-CNM) Artículos
Files in This Item:
File Description SizeFormat 
cancer_biomarkers_Kosaka.pdf1,35 MBAdobe PDFThumbnail
Show simple item record

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.